WO2007122755A1 - スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体 - Google Patents
スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体 Download PDFInfo
- Publication number
- WO2007122755A1 WO2007122755A1 PCT/JP2006/320496 JP2006320496W WO2007122755A1 WO 2007122755 A1 WO2007122755 A1 WO 2007122755A1 JP 2006320496 W JP2006320496 W JP 2006320496W WO 2007122755 A1 WO2007122755 A1 WO 2007122755A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- dimethyl
- sodium salt
- methoxy
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a salt of a sulfielbenzimidazole compound useful as a gastric acid secretion inhibitor, a crystal thereof, and an amorphous body.
- the present invention also relates to free crystalline and amorphous sulfinylbenzimidazole compounds.
- Peptic ulcers such as gastric ulcers and duodenal ulcers are thought to occur as a result of the balance between attack factors such as acid and pepsin and defense factors such as mucus and blood flow causing self-digestion. Yes.
- Patent Document 1 Pamphlet of International Publication No. 91Z19712
- Patent Document 2 JP-A-59-181277
- an object of the present invention is to provide various salts, crystals thereof and amorphous materials for the compound (1).
- Another object of the present invention is to provide a crystal and an amorphous form of the compound (1).
- the present invention relates to the following [1] to [63].
- the salt is a salt selected from the group consisting of potassium salt, magnesium salt, lithium salt, calcium salt, or zinc salt strength.
- a salt crystal (a sodium salt A-type crystal) according to [2], having a chemical shift ( ⁇ 0.5 ppm) and peak at 16.7 ppm in a 13 C solid state NMR spectrum.
- a salt crystal according to [2] (B-type crystal of sodium salt) having a chemical shift ( ⁇ 0.5 ppm) and a peak at 25.3 ppm in a 13 C solid state NMR spectrum.
- a medicine comprising the salt, crystal or amorphous substance according to any one of [1] to [55-11].
- a gastric acid secretion inhibitor comprising the salt, crystal or amorphous substance according to any one of [1] to [55-11].
- a therapeutic and Z or preventive agent for a disease caused by gastric acid comprising the salt, crystal or amorphous substance according to any one of [1] to [55-11].
- Gastric ulcer diseases caused by gastric acid include gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis (including those that relapse and recur), Zollinger-Ellison syndrome, symptomatic reflux esophagitis, endoscopic negative Reflux esophagitis, non-erosive reflux esophagitis, gastroesophageal reflux disease, NUD (Non- Ulcer Dyspepsia) (non-ulcer dyspepsia), pharyngeal and laryngeal abnormalities, Barrett esophagus, NSAID ulcer, gastritis, gastric bleeding, bleeding Gastritis, gastrointestinal bleeding, peptic ulcer, hemorrhagic ulcer, stress ulcer, gastric hyperacidosis, dyspepsia, gastric failure, elderly ulcer, refractory ulcer, acute gastric mucosal lesion, heartburn, sleep apnea Heartburn, bruxism, stomach pain,
- a disinfectant or disinfectant for sterilization of Lycopacter pylori into the stomach comprising the salt, crystal or amorphous substance according to any one of [1] to [55-11].
- the structural formula of a compound may represent a certain isomer for convenience.
- the present invention includes all optical isomers and isomer mixtures generated in the structure of the compound for convenience. Any one of the isomers or a mixture may be used. Therefore, the compound of the present invention may exist in an optically active form and a racemic form, but is not limited in the present invention and includes both.
- a crystalline polymorph may be present in an amorphous form, but is not limited in the same manner. Any crystalline form, an amorphous single substance or a mixture may be used.
- Such compounds include anhydrides, solvates, embodiments in which a solvent is attached (for example, crystals containing attached water), and embodiments in which a solvent is contained in a solid.
- Crystal and “amorphous body” of the present invention are not particularly limited as long as the “crystal” or “amorphous body” is included, unless otherwise specified. It may be a pure embodiment, or an embodiment containing other crystalline polymorphs or amorphous bodies. Note that an embodiment in which a small amount of the “crystal” or “amorphous body” is also included in the “crystal” or “amorphous body” of the present invention.
- the “salt” in the present specification is not particularly limited as long as it is a salt of compound (1) and a base.
- the base in the NH group at the 1- or 3-position of the benzimidazole skeleton, Forms a salt with a base.
- the base forms a salt at an appropriate ratio of 0.1 to 5 molecules per molecule of the compound, and preferably in the case of a salt with a monovalent base (such as sodium),
- the base forms a salt at an appropriate ratio of about 1 molecule per molecule of the compound.
- a salt with a divalent base such as magnesium
- the base is about 0 per molecule of the compound. 5.
- the "solvate” of the present invention is not particularly limited as long as it is a solvent used in the production of salts and crystals. Specific examples include, but are not limited to, hydrates, ethanol solvates, acetone solvates, toluene solvates, tert-butyl methyl ether solvates, and the like, and toluene solvates are preferred.
- the above diffraction angle value is a value within the range of ⁇ 0.2 °. Need to be understood as including. Therefore, a crystal in which the peak (diffraction angle) in the powder X-ray diffraction only coincides with a crystal having a perfectly matched peak (diffraction angle) with an error of about ⁇ 0.2 ° is also included in the present invention.
- “having a diffraction peak at diffraction angle (2 0 ⁇ 0.2 °) 4.9 °” means “diffraction angle (2 ⁇ ) 4.7 ° to 5. It has a diffraction peak at 1 °.
- the wave number (cm- 1 ) in the infrared absorption spectrum can have an error within a range of 2cm_1 , so the above wavenumber value is about ⁇ 2cm_1 It should be understood to include numerical values within the range.
- AT R method in the absorption peak (wavenumber) of crystals only Nag absorption peaks coinciding completely (wave number) Agassi matching crystals present invention at 2 cm _1 about errors.
- wavenumber having an absorption peak at ( ⁇ 2cm _1) 827cm _1 means “having an absorption peak at a wavenumber 825 ⁇ 829Cm _1".
- a chemical shift ( ⁇ 0.5 ppm) having a peak at 16.7 ppm means "under normal measurement conditions or substantially the same conditions as in the present specification.”
- a 13 C solid NM R spectrum was measured and had a peak substantially equivalent to a chemical shift of 16.7 ppm. '' Specifically, it means “having a peak at ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ shift 16.2-17.2ppm”.
- the "half-width of peak” means the lateral width (ppm) of a peak when the peak shape is cut in the lateral direction at a position half the height of the peak.
- a combination of measurements of the vector or 15 N solid-state NMR ⁇ vector allows the crystalline or amorphous form contained in the composition such as the drug product or in the drug substance (the number of each crystal in the free form or salt). Including all forms, amorphous, solvates and anhydrides).
- the measurement method and conditions are not particularly limited as long as they are generally used devices and conditions, but specifically, for example, measurement can be performed with the devices and conditions described in the following examples.
- the peak of the additive used in the preparation or the like is not detected. Therefore, even when the amount is small, or when crystals or amorphous substances are contained, each crystal or The form of the amorphous body can be examined.
- compositions such as X-ray diffraction, infrared absorption spectrum (ATR method (total reflection measurement method)), 13 C solid state NMR spectrum, and Z or 15 N solid state NMR spectrum
- ATR method total reflection measurement method
- 13 C solid state NMR spectrum 13 C solid state NMR spectrum
- Z or 15 N solid state NMR spectrum a method for examining the form of crystals or amorphous substances contained in the drug substance.
- [X2] A method for investigating the form of crystals or amorphous substances contained in a composition such as a drug product or in an active pharmaceutical ingredient using 15 N solid-state NMR spectroscopy.
- Examples of 15 N solid state NMR spectrum measurement conditions include the following conditions.
- the "disease or symptom caused by gastric acid” is not particularly limited as long as it is a disease or symptom caused by gastric acid.
- Preferable examples include gastric ulcer, duodenal ulcer, anastomosis ulcer, reflux esophagus Inflammation, Zollinger-Ellison syndrome, symptomatic reflux esophagitis, endoscope negative reflux esophagitis, non-erosive reflux esophagitis, acute gastric mucosal lesions, etc.
- Reflux esophagitis, symptomatic reflux esophagitis, gastric ulcer, or duodenal ulcer can be mentioned, and more preferable examples are (1) reflux esophagitis or symptomatic reflux esophagitis, or ( 2) A gastric ulcer or a duodenal ulcer can be given.
- prophylactic agent includes those administered before the onset of a disease or symptom, as well as maintenance therapeutic agents or preventive agents after recurrence.
- sterilization aid refers to a drug that is difficult to be effective under acidic conditions and that provides an environment in which the sanitizer is effective.
- the salt, crystal or amorphous form of the compound (1) of the present invention has an excellent gastric acid secretion inhibitory action and has excellent physical properties as a medical drug, reflux esophagitis and symptomatic properties. It is useful as a therapeutic or prophylactic agent for reflux esophagitis, gastric ulcer or duodenal ulcer.
- FIG. 1 is a diagram showing a 13 C solid state NMR spectrum of a sodium salt type A crystal obtained in Example 2X.
- FIG. 2 is a diagram showing a 13 C solid state NMR spectrum of a sodium salt type A crystal obtained in Example 2X.
- FIG. 3 is a diagram showing a 13 C solid state NMR spectrum of a sodium salt B-type crystal obtained in Example 4X.
- FIG. 4 is a diagram showing a 13 C solid state NMR spectrum of a sodium salt B-type crystal obtained in Example 4X.
- FIG. 5 is a diagram showing a 13 C solid state NMR spectrum of a sodium salt C-type crystal obtained in Example IX.
- FIG. 6 is a diagram showing a 13 C solid state NMR spectrum of a sodium salt C-type crystal obtained in Example IX.
- FIG. 7 is a diagram showing a 13 C solid state NMR spectrum of a sodium salt D-type crystal obtained in Example 5X.
- FIG. 8 is a view showing a 13 C solid state NMR spectrum of a sodium salt D-type crystal obtained in Example 5X.
- FIG. 9 is a diagram showing a 13 C solid state NMR spectrum of an amorphous sodium salt obtained in Example 9X.
- FIG. 10 is a diagram showing a 13 C solid state NMR spectrum of an amorphous form of a sodium salt obtained in Example 9X.
- FIG. 11 shows 13 C solid state NMR spectra of the free amorphous material obtained in Example 3Y.
- FIG. 12 is a diagram showing an infrared absorption spectrum (ATR method) of a sodium salt A-type crystal obtained in Example 2X.
- FIG. 13 is a diagram showing an infrared absorption spectrum (ATR method) of a sodium salt B-type crystal obtained in Example 4X.
- FIG. 14 is a diagram showing an infrared absorption spectrum (ATR method) of a sodium salt C-type crystal obtained in Example IX.
- FIG. 15 is a diagram showing an infrared absorption spectrum (ATR method) of a sodium salt D-type crystal obtained in Example 5X.
- FIG. 16 is a diagram showing an infrared absorption spectrum (ATR method) of an amorphous sodium salt obtained in Example 9X.
- FIG. 17 is a diagram showing an infrared absorption spectrum (ATR method) of a free amorphous material obtained in Example 3Y.
- FIG. 18 is a diagram showing a powder X-ray diffraction pattern of a sodium salt A-type crystal obtained in Example 2X.
- FIG. 19 is a view showing a powder X-ray diffraction pattern of a sodium salt B-type crystal obtained in Example 4X.
- FIG. 20 is a view showing a powder X-ray diffraction pattern of a sodium salt C-type crystal obtained in Example IX.
- FIG. 21 is a diagram showing a powder X-ray diffraction pattern of a sodium salt D-type crystal obtained in Example 5X.
- FIG. 22 is a diagram showing a powder X-ray diffraction pattern of a sodium salt E-type crystal obtained in Example 8X.
- FIG. 23 is a diagram showing a powder X-ray diffraction pattern of a sodium salt F-type crystal obtained in Example 10X.
- FIG. 24 is a view showing a powder X-ray diffraction pattern of a sodium salt G-type crystal obtained in Example 6X.
- FIG. 25 shows a powder X-ray diffraction pattern of a sodium salt H-form crystal obtained in Example 7X.
- FIG. 26 is a diagram showing a powder X-ray diffraction pattern of an amorphous sodium salt obtained in Example 3X.
- FIG. 27 is a diagram showing a powder X-ray diffraction pattern of an amorphous sodium salt obtained in Example 9X.
- FIG. 28 is a diagram showing a powder X-ray diffraction pattern of a free-form A-type crystal obtained in Example 1Y.
- FIG. 29 is a view showing a powder X-ray diffraction pattern of a free-form B-type crystal obtained in Example 2Y.
- FIG. 30 is a diagram showing a powder X-ray diffraction pattern of a free amorphous material obtained in Example 3Y.
- FIG. 31 is a diagram showing a powder X-ray diffraction pattern of a magnesium salt crystal obtained in Example 2Z.
- FIG. 32 is a diagram showing a powder X-ray diffraction pattern of crystals of potassium salt obtained in Example 1Z.
- FIG. 33 is a graph showing a powder X-ray diffraction pattern of a lithium salt crystal obtained in Example 3Z.
- FIG. 34 is a view showing a powder X-ray diffraction pattern of a zinc salt crystal obtained in Example 4Z.
- FIG. 35 is a view showing a powder X-ray diffraction pattern of a calcium salt crystal obtained in Example 5Z.
- the salt of the compound (1) of the present invention can be produced by the method described below. However, the production method of the compound of the present invention is not limited thereto.
- Compound (1) can be synthesized according to the following examples.
- Compound (1) used for the production of the salt may be in any form.
- hydrates and anhydrides both amorphous and crystalline (including multiple crystalline polymorphs)
- the solid of the compound (1) may be added, or a mixture of the compound and the solvent (solution, suspension, slurry state, etc.) may be added.
- the base used for the production of the salt is not particularly limited as long as it is a base that can be mixed with the free form of the compound (1) to produce the salt of the compound (1).
- a base that can be mixed with the free form of the compound (1) to produce the salt of the compound (1).
- the base used for the production of the salt may be added without dissolving the basic substance in the solution, or may be added with a basic solution obtained by dissolving the basic substance in water or an organic solvent.
- the salt of compound (1) is produced, it is not particularly limited as long as it is a commonly used operation method. Specifically, for example, the salt of compound (1) is obtained by the following procedure. be able to. After the compound (1), the base and the solution are mixed, the mixture is stirred, allowed to stand or the solvent is distilled off to precipitate the salt of the compound (1). The precipitated salt is separated by a normal filtration operation, washed with an appropriate solvent (usually the same as the solvent used for the precipitation) as necessary, and further dried to obtain a salt of the compound of the present invention.
- an appropriate solvent usually the same as the solvent used for the precipitation
- a salt of compound (1) and a base is formed, it is further mixed with a solvent, and this mixture is stirred, allowed to stand or evaporated to remove compound (1). Precipitate the salt.
- the precipitated salt can be separated by a normal filtration operation, washed with an appropriate solvent (usually the same solvent used for precipitation) as necessary, and further dried to obtain a salt of the compound of the present invention. .
- Solvents used for the production of salts include ketones such as methyl ethyl ketone and acetone, alcohols such as methanol, ethanol, isopropanol and n-propanol, esters such as ethyl acetate and methyl acetate. , Hydrocarbons such as hexane and heptane, Typical examples include, but are not limited to, ethers such as trahydrofuran, jetyl ether and dioxane, force rubonic acids such as acetic acid, or water, or a mixed solvent thereof.
- the amount of the solvent used is the lower limit of the amount of the compound (1) and each base mixed by heating (for example, dissolution, suspension, slurry state, etc.), and the salt yield is not significantly reduced!
- the upper limit can be selected appropriately. What is necessary is just to select suitably the temperature which mixes a compound (1) and each base according to a solvent.
- the final cooling temperature can be appropriately selected from the yield and quality of the salt, but is preferably room temperature to 0 ° C.
- the salt of the present invention may be precipitated by adding a poor solvent (hexane, heptane, etc.) to a solution obtained by mixing the compound (1) and each base.
- a poor solvent hexane, heptane, etc.
- the salt separated by the filtration operation can be dried by leaving it in the air. However, when it is produced in a large amount, it may be dried by efficient heating.
- the drying temperature can be appropriately selected according to the production amount.
- the drying time may be appropriately selected according to the production amount, the drying apparatus, the drying temperature, etc. until the residual solvent falls below a predetermined amount. Further, drying can be performed under ventilation or under reduced pressure, but is preferably performed under reduced pressure.
- the degree of vacuum may be appropriately selected according to the production amount, drying apparatus, drying temperature, and the like.
- A-type crystals of the sodium salt of compound (1) can be produced.
- the sodium salt of the compound (1) used for the crystallization is a mixture of these solvates, anhydrides, amorphous, or crystalline. May
- Examples of the solvent used for the crystallization include an alcohol solvent, an ether solvent, an alkyl ketone solvent, and a mixed solvent of two solvents selected from the group consisting of alkyl solvent powers, A mixed solvent of ethanol and methyl t-butyl ether is preferred.
- the mixing ratio (volume ratio) is preferably 2:13 to 1: 7, more preferably 1: 9 to 1:10.
- the amount of the solvent used can be appropriately selected with the lower limit being the amount by which the sodium salt of compound (1) is dissolved by heating, and the upper limit being the amount that does not significantly reduce the yield of crystals. Is a volume ratio of 15 to 40 times (vZw), preferably 20 to 35 times the amount 7) of the sodium salt of compound (1).
- the temperature at which the sodium salt of compound (1) is dissolved by heating may be appropriately selected according to the solvent, and preferably the reflux temperature of the crystallization solvent. To room temperature, more preferably room temperature.
- the final crystallization temperature can be appropriately selected from the yield and quality of the crystal, but is preferably 0 to 30 ° C.
- a seed crystal (a small amount of the A-type crystal of the sodium salt of compound (1)) may or may not be added.
- the crystallized crystal can be separated by a normal filtration operation, washed with a solvent as necessary, and dried to obtain the desired crystal.
- the solvent used for washing the crystals is a force common to the crystallization solvent, preferably a mixed solvent of ethanol and methyl t-butyl ether (1: 9 to 1:10).
- the crystals separated by the filtration operation can be dried by leaving them at room temperature under a nitrogen stream or under caloric heat. Drying can also be performed under reduced pressure. The degree of vacuum may be appropriately selected according to the production amount, drying apparatus, drying temperature, and the like.
- the time required for the residual solvent to fall below a predetermined amount should be appropriately selected according to the production amount, drying apparatus, drying temperature, and the like.
- (A) Compound (1) and solvent (alcohol solvent such as methanol and ethanol) are mixed to prepare a solution containing compound (1).
- the solution containing the compound (1) the extracted solution after the reaction treatment obtained in the production of the compound (1) according to Examples and the like can be used as it is. That is, in the production of compound (1), extraction is performed with a solvent (an alkyl ketone solvent such as methyl isobutyl ketone, an ester solvent such as ethyl acetate) during the treatment after the reaction, and the resulting compound (1)
- a solvent an alkyl ketone solvent such as methyl isobutyl ketone, an ester solvent such as ethyl acetate
- the solution containing can be used as it is without isolating and purifying the compound (1).
- the mixture is further mixed with another solvent (an alkyl solvent such as hexane or heptane, a cycloalkyl solvent such as cyclohexane, or an ether solvent such as jetyl ether).
- an alkyl solvent such as hexane or heptane
- a cycloalkyl solvent such as cyclohexane
- an ether solvent such as jetyl ether
- Ester solvents such as ethyl acetate).
- the compound (1) used for crystallization may be in any form of solvate, anhydride, amorphous, crystalline, or a mixture thereof. .
- the extract after the reaction treatment without isolating compound (1) can be used as it is.
- Examples of the solvent used for crystallization include one solvent selected from the group consisting of ether solvents, ester solvents, and alcohol solvents, or a mixed solvent of two or more solvents.
- ether solvents methyl t-butyl ether, methyl isobutyl ketone, and ethyl acetate are preferable.
- mixed solvent 1 propanol and methyl t-butyl ether, 2-propanol and methyl t-butyl ether, 1-butanol and methyl t-butyl ether, methyl isobutyl ketone and methyl t-butyl ether or ethanol and methyl t-butyl ether are preferred! / ,.
- the mixing ratio (volume ratio) is preferably 1: 100 to 1: 1, and more preferably 1:60 to 1: 2.
- the amount of the solvent used is a power that can be appropriately selected with the lower limit of the amount at which the free form dissolves at room temperature and the upper limit of the amount that does not significantly reduce the yield of crystals, preferably the weight of compound (1).
- the volume ratio is 5 to 50 times (vZw), preferably 8 to 35 times (vZw).
- the crystallized crystal is separated by a normal filtration operation, washed with a solvent as necessary, and further dried to obtain a target crystal.
- the solvent used for washing the crystal is a force common to the crystallization solvent, preferably a single solution of methyl t-butyl ether, ethyl acetate, methyl isobutyl ketone or a mixed solution of methyl t-butyl ether and methyl isobutyl ketone. .
- the crystals separated by the filtration operation can be appropriately dried by being left in a nitrogen stream or by heating. Drying can be performed in a nitrogen stream or under reduced pressure. Decompression The degree may be appropriately selected according to the production amount, the drying device, the drying temperature, and the like. For the drying time, the time required for the residual solvent to fall below a predetermined amount should be appropriately selected according to the production amount, drying apparatus, drying temperature, and the like.
- (A) Compound (1) and a solvent are mixed to prepare a solution containing compound (1).
- the solution containing the compound (1) the extracted solution after the reaction treatment obtained in the production of the compound (1) according to Examples and the like can be used as it is. That is, in the production of compound (1), extraction is performed with a solvent (such as toluene or a mixed solvent containing toluene) during the treatment after the reaction, and the resulting solution containing compound (1) is converted into compound (1 ) Can be used as is without isolation and purification.
- a solvent such as toluene or a mixed solvent containing toluene
- a base sodium hydroxide, sodium alkoxide, etc., or a solution thereof for forming a sodium salt is prepared.
- Another solvent an alkyl solvent such as hexane or heptane, a cycloalkyl solvent such as cyclohexane, an ether solvent such as jetyl ether is added to the mixture.
- the sodium salt of the compound (1) used for the crystallization is a mixture of these solvates, anhydrides, amorphous or crystalline, which may be in any form. May be. After the production of compound (1), the extract after the reaction treatment without isolating compound (1) can be used as it is.
- Solvents used for crystallization are benzene-based solvents such as benzene and toluene, hexane, and hexane.
- An alkyl solvent such as pentane, a cycloalkyl solvent such as cyclohexane, an ether solvent, and a mixed solvent of two or more solvents selected from the group consisting of an ether solvent and an alcohol solvent are preferable.
- a mixed solvent of toluene, methyl t-butyl ether and methanol may be added separately.
- the mixing ratio (volume ratio) when using a mixed solvent of toluene or methyl t-butyl ether is preferably 2: 1 to 1: 2, more preferably 9: 6 to 7: 9.
- the amount of methanol used (volume ratio) is preferably 0.2 to 0.6, and more preferably 0.3 to 0.5.
- the amount of the solvent used is a power that can be appropriately selected with the lower limit of the amount in which the free form dissolves at room temperature and the upper limit of the amount that does not significantly reduce the yield of crystals, preferably the weight of compound (1).
- the volume ratio is 10 to 50 times (vZw), preferably 20 to 35 times (vZw).
- the crystallized crystal is separated by a normal filtration operation, washed with a solvent as necessary, and dried to obtain the desired crystal.
- the solvent used for washing the crystals is a force common to the crystallization solvent, preferably a mixed solvent of toluene and methyl t-butyl ether (9: 6-7: 8).
- the crystals separated by the filtration operation can be appropriately dried by being left under a nitrogen stream or by heating. Drying can be performed in a nitrogen stream or under reduced pressure. The degree of vacuum may be appropriately selected according to the production amount, the drying apparatus, the drying temperature, and the like.
- the time required for the residual solvent to fall below a predetermined amount should be appropriately selected according to the production amount, drying apparatus, drying temperature, and the like.
- an amorphous form of the sodium salt of compound (1) can be produced with reference to the following examples (lyophilization method).
- a sodium salt of compound (1) and a solvent are mixed.
- the sodium salt of the compound (1) used in the production is a mixture of these solvates, anhydrides, amorphous forms, and crystalline forms. There may be.
- Examples of the solvent to be used include one solvent selected from the group consisting of an alcohol solvent and water, or a mixed solvent of two solvents, preferably water.
- the ratio (volume ratio) is 3 to 20 times (vZw), preferably 5 to 10 times (vZw) by volume ratio of the sodium salt of compound (1). Ah.
- the amorphous substance separated by the filtration operation can be dried at room temperature or by heating.
- Drying can also be performed under reduced pressure.
- the degree of vacuum may be appropriately selected according to the production amount, drying apparatus, drying temperature, and the like.
- the drying time may be appropriately selected according to the production amount, drying apparatus, drying temperature, etc. until the residual solvent falls below a predetermined amount.
- an amorphous form of the sodium salt of compound (1) By pulverizing the sodium salt of compound (1) (for example, pulverization using a pulverizer such as a mortar or ball mill), an amorphous form of the sodium salt of compound (1) can be obtained.
- the sodium salt of the compound (1) used for the production is a mixture of these, which may be a solvate, an anhydride, an amorphous form or a crystalline form, in any form. Also good.
- an amorphous form of the sodium salt of Compound (1) can be produced.
- An amorphous form of the sodium salt of compound (1) can be obtained by spray drying the sodium salt of compound (1).
- the sodium salt of compound (1) used in the production may be in any form, solvate, anhydride, amorphous or crystalline, or a mixture thereof.
- Solvent used can dissolve the sodium salt of compound (1) Any of water, an organic solvent, and a mixture thereof may be used.
- the salt or crystal of the present invention When used as a medicine, the salt or crystal of the present invention and a suitable additive are usually mixed and formulated. However, it does not deny that the salt and the crystal of the present invention are used as a drug as it is.
- additives examples include excipients, binders, lubricants, disintegrants, coloring agents, flavoring agents, emulsifiers, surfactants, solubilizers, and suspensions that are generally used in medicine.
- excipients include lactose, sucrose, glucose, corn starch, mannitol, sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, light anhydrous carboxylic acid, aluminum silicate, calcium silicate, and metasilicate. Examples thereof include magnesium aluminate acid and calcium hydrogen phosphate.
- binder examples include polybulal alcohol, methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylinole pyrrolidone, macrogol and the like. Can do.
- Examples of the lubricant include magnesium stearate, calcium stearate, sodium stearyl fumarate, talc, polyethylene glycol, colloidal silica and the like.
- disintegrant examples include crystalline cellulose, agar, gelatin, calcium carbonate, sodium hydrogen carbonate, calcium citrate, dextrin, pectin, low-substituted hydroxypropenoresenorelose, canoleoxy methinoresenorelose, canolevo Examples thereof include xymethinoresenorelose canoleum, croscarmellose sodium, carboxymethyl starch, and carboxymethyl starch sodium.
- colorants it is allowed to be added to pharmaceuticals such as tri-iron oxide, yellow tri-iron oxide, carmine, caramel, ⁇ -strength rotin, titanium oxide, talc, riboflavin sodium phosphate, yellow aluminum lake, etc. Can be mentioned.
- flavoring agents examples include cocoa powder, heart-bending brain, fragrance powder, heart-strength oil, dragon brain, and cinnamon powder. I can make it.
- emulsifiers and surfactants examples include stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, glyceryl monostearate, sucrose fatty acid ester, glycerin fatty acid ester and the like.
- solubilizer examples include polyethylene glycol, propylene glycol, benzoic acid benzyl, ethanol, cholesterol, triethanolamine, sodium carbonate, sodium citrate, polysorbate 80, nicotinamide, and the like.
- suspending agent in addition to the above surfactant, polyvinyl alcohol, polyvinylpyrrolidone, methinoresenorelose, hydroxymethinoresenorelose, hydroxyethinoresenorelose, hydroxypropylcellulose, etc. Mention may be made of molecules.
- Examples of the isotonic agent include glucose, sodium chloride salt, mannitol, sorbitol and the like.
- buffer solutions of phosphate, acetate, carbonate, citrate, and the like examples include buffer solutions of phosphate, acetate, carbonate, citrate, and the like.
- Examples of the preservative include methyl paraben, propyl paraben, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid, a-tocopherol and the like.
- Examples of the stabilizer include those generally used in medicine.
- absorption promoter examples include those generally used in medicine.
- oral preparations such as tablets, powders, granules, capsules, syrups, troches, and inhalants; suppositories, ointments, eye ointments, tapes, eye drops, Nasal drops, ear drops
- Topical preparations such as knops and lotions or injections.
- the oral preparation is formulated by appropriately combining the above additives. If necessary, these surfaces can be coated.
- external preparations include excipients, binders, flavoring agents, emulsifiers, surfactants, solubilizers, suspending agents, isotonic agents, preservatives, antioxidants, among others.
- An appropriate combination of agents, stabilizers or absorption enhancers is formulated.
- injections are emulsifiers, surfactants, solubilizers, suspending agents, isotonic agents, buffers, preservatives, antioxidants, stabilizers, or absorption enhancers.
- the drug is formulated with appropriate combinations.
- a preparation containing a salt, a crystal, or an amorphous form of the compound (1) of the present invention for use in treatment or prevention for humans is a pharmacologically commonly used method or It can be obtained by the following formulation example.
- the amount used varies depending on the symptoms and age S, usually in the case of an oral preparation, 0.15 to 5000 mg (preferably ⁇ or 0.5 to 5 1500 mg), 0.5 to 1500 mg (preferably 1.5 to 500 mg) for external preparations, 0.3 to 5000 mg (preferably 1 to 500 mg) for injections, once a day Use in divided doses or in 2 to 6 divided doses.
- 0.15 to 5000 mg preferably ⁇ or 0.5 to 5 1500 mg
- 0.5 to 1500 mg preferably 1.5 to 500 mg
- 0.3 to 5000 mg preferably 1 to 500 mg
- the salt, crystal, and amorphous form of the compound (1) of the present invention can be produced, for example, by the method described in the following examples. It can be confirmed by the method described in. However, these are only examples, and the present invention is not limited to the following specific examples in any case, and may be changed within the scope without departing from the scope of the present invention!
- the obtained crude product was stirred for 2 hours in a mixture of diisopropyl ether (500 mL) and n-hexane (1.0 L), and then suction filtered. The obtained wet body was vacuum-dried overnight to obtain 666.4 g of the desired product.
- the ethyl acetate layer was separated, and the aqueous layer was extracted with ethyl acetate (1.0 L X 3). The combined ethyl acetate layer was filtered through celite and concentrated under reduced pressure to obtain 1.20 kg of the desired product.
- Diisopropyl ether (3.5 L) was added to the obtained yellow crystals and dissolved at 50 ° C. Insoluble matter was removed by filtration, and then slow cooling was performed, followed by aging at 5 ° C overnight. The obtained crystals were filtered, washed with heptane (0.5 L), and air-dried to obtain 0.69 kg of the desired product.
- the obtained organic layer was concentrated under reduced pressure (40 ° C.) to obtain a brown oily substance (2.40 kg, containing 1446 mL of toluene and 168 mL of tetrahydrofuran, calculated from a ⁇ -NMR ⁇ vector).
- the compound (4) may be a crystalline form of the compound (4) described below, an amorphous form or a mixture thereof! /, .
- Example IX (R) — 2— ( ⁇ “4— (2. 2 Dimethyl-1,3 Dioxane, 5-yl) Methoxy-3,5 Dimethylviridine-2-yl (methyl 1sulfiel) —1H Benzoimidazole sodium (sodium C-type crystal)
- L-(+)-Jetyl tartrate (122.9 g, 0. 596 mol) was added to this suspension and washed with toluene (560 mL). After 30 minutes, dissolution was confirmed. After 8 minutes, titanium (IV) tetraisopropoxide (77.0 g, 0.271 mol) was added, washed with toluene (56 mL), and heated and stirred at the same temperature for about 1 hour. The temperature was changed to 8 ° C cooling, and N, N diisopropylethylamine (56.01 g, 0.742 mol) was added and washed with toluene (280 mL).
- C-type crystals of sodium salt About 13 hours after tert-butyl methyl ether was added dropwise, the precipitated crystals were collected by suction filtration, rinsed with toluene Ztert-butyl methyl ether (1047 mL Zl 93 mL), and then suction-dried for 15 minutes. The obtained wet crystals were dried under reduced pressure (40 ° C.) to obtain crystals of the title compound (hereinafter referred to as “C-type crystals of sodium salt”).
- tert butyl methyl ether 25. 80 kg was added at 20 ° C with stirring for 14 minutes. It was dripped over the period. The mixture was further stirred for 1 hour and 1 minute, tert-butylmethyl ether (145.93 kg) was added dropwise over 2 hours and 46 minutes, and then stirred at 20 ° C for 17 hours and 45 minutes.
- the precipitate formed in the mixture was collected by filtration, washed with a mixture of ethanol (2. 30 L) and tert-butyl methyl ether (15.50 kg), and then washed with tert butyl methyl ether (17. 23 kg). , Dried under reduced pressure at 50 ° C. for about 36 hours, passed through a sieve (aperture 1. OOmm), and white crystals of the title compound (hereinafter referred to as “sodium salt type A crystals”) (10. 02kg) Got.
- the compound (4) was heated for 2 hours at 80 ° C (external temperature) under reduced pressure (lmmHg) under an evaporator intermittent rotation (lmin./pause: 3se./rotation), and then under reduced pressure ( lm mHg) Heated at 100 ° C (external temperature) for 6 hours, then sealed under normal pressure and stored at 23 to 25 ° C.
- MIBK methylisobutylketone
- Example 7X (R) — 2— ( ⁇ “4— (2.2 Dimethyl-1-1.3-dioxane-1-yl) methoxy-3.5 3.5 Dimethylviridine-2-yl ⁇ methyl ⁇ sulfinyl ) 1H Benzimidazol sodium salt (sodium salt cocoon crystal)
- the compound (4) cerium salt G-form crystal obtained in Example 6X was stored at about 60 ° C. for 1 week and referred to as the title compound crystal (hereinafter referred to as “sodium salt H-form crystal”). )
- reaction mixture was charged with N, N diisopropylethylamine (337 L) at 19.8 ° C. (internal temperature).
- Tamen hydroperoxide (80%, 1.15g) and toluene (5. OmL) at 5 ° C (external temperature) were heated at 0.2 ° C for 3 minutes at 1 ° C. .
- the reaction mixture was cooled to ⁇ 5 ° C. (external temperature), 30% aqueous sodium thiosulfate solution (10 g) was added, and the mixture was stirred sufficiently, and then the organic layer was separated.
- a 1N aqueous sodium hydroxide solution (10 mL) was added to the organic layer, and after sufficient stirring, the aqueous layer was separated.
- MIBK (20 mL) was added to the resulting aqueous layer, and a 20% aqueous acetic acid solution was gradually added so that the pH was 7.3.
- the organic layer was separated, and a solution of sodium tert pentoxide (701 mg) in toluene (7 mL) was added dropwise to the organic layer.
- E-type crystals of sodium salt The pale yellow crystals were further stored at 60 ° C. for 10 days to obtain crystals of the title compound (hereinafter referred to as “E-type crystals of sodium salt”).
- reaction mixture was cooled to 3 ° C and then tamen hydroperoxide (80%, 4.47 mL) was added over 20 minutes at -1.0 to 0.6 ° C, The reaction mixture was stirred between -1 ° C and 1 ° C for 21 hours and 35 minutes.
- a 30% aqueous sodium thiosulfate solution (38.4 mL) was added to the reaction mixture at 0.6 ° C to 2.7 ° C, and after sufficient stirring, the organic layer was separated.
- a 1N sodium hydroxide aqueous solution (38.4 mL) was added to the organic layer, and after sufficient stirring, the aqueous layer was separated.
- tert butyl methyl ether 38.4 mL was added, and a 20% aqueous acetic acid solution was gradually added so that the pH became 9.87 while stirring.
- the uppermost layer (organic layer 1) was collected. After adding tert butyl methyl ether (40 mL) to the lower two layers, a 20% aqueous acetic acid solution was gradually added while stirring so that the pH was 9.17. The upper layer (organic layer 2) was separated, and the remaining aqueous layer was added with ethyl acetate (30 mL) and stirred sufficiently, and then the organic layer (organic layer 3) was separated. The organic layers 1 to 3 were combined, dried over anhydrous magnesium sulfate (15 g), filtered, and the solvent was distilled off from the filtrate under reduced pressure.
- N, N diisopropylethylamine (225 L) was added at 2 ° C, and then from 3.3 ° C to 2.2 ° C tamen hydroperoxide (80%, 224 L) was added.
- Hyflo Supercell [107.4 g, ethanol / tert-butyl methyl ether (1074 mL / 1074 mL), sequentially washed with tert-butyl methyl ether (537 mL)] Hyflo Supercell was washed with ethanol / tert-butyl methyl ether (215 mL / 215 mL).
- Example 2Q 2-( ⁇ ⁇ 4-(2.2 dimethyl-1.3 dioxan-5-yl) methoxy-3.5 dimethylpyridine-2-yl ⁇ methyl 1-sulfinyl) 1H -benzimidazole (racemic)
- Benidoimidazo “L” was a photoactive substance that eluted later when analyzed under the above HPLC analysis conditions (enantiomeric excess).
- Example compounds were examined using a large dog (weight approximately 14-19 kg) equipped with a chronic gastrostomy tube. The experiment was conducted over 2 days. On the first day, gastric juice was collected every 20 minutes under the condition that histamine (50 or 75 gZkgZh) was administered intravenously for 3 hours. One hour after the start of histamine administration, the Example compounds suspended or dissolved in 0.5% methylcellulose solution were administered via a catheter placed in the duodenum at a volume of 0.1 ml / kg. Thereafter, the gastric acid secretion inhibitory action of the example compounds was examined over 2 hours.
- histamine 50 or 75 gZkgZh
- gastric juice was collected every 20 minutes under the condition of intravenous administration of histamine for 2 hours, and the gastric acid secretion inhibitory action was examined.
- gastric juice 0.5 ml of gastric juice was sampled, and neutralized with a 0.04 mol / l aqueous solution of sodium hydroxide in sodium hydroxide to determine the acid concentration.
- the amount of gastric acid excretion was determined by multiplying the gastric juice volume by the acid concentration.
- the gastric acid secretion inhibitory action was evaluated by the gastric acid secretion inhibition rate (%) on the first day.
- the gastric acid secretion inhibitory action (%) was determined from the following formula. When the number of cases was 2 or more, the average value of all cases was obtained and shown.
- [B] Gastric acid excretion during 20 minutes from 1 hour 40 minutes to 2 hours after administration of the example compound The duration of the gastric acid secretion inhibitory action was evaluated by the gastric acid secretion inhibition rate (%) on the second day. The gastric acid secretion inhibitory action duration (%) was determined from the following formula.
- Compound A 30 Og, Ethylcellulose (trade name: Ethosel, Dow Chemical Co.) 8. lg and Hydroxypropylcellulose (trade name: HPC—L, Shin-Etsu Chemical Co., Ltd.) 16.2 g into 48 9 g of absolute ethanol Dissolved. This solution is coated on 500. lg of non-barrel 108 (trade name, Freund Sangyo), which is the core material, using a Wurster type fluidized bed granulation coating machine (trade name: multiplex, PAREC), and the granules are dried. Obtained.
- ethylcellulose (trade name: etosel, Dow Chemical Co., Ltd.) 48.6 g and hydroxypropylcellulose (trade name: HPC-L, Shin-Etsu Chemical Co., Ltd.) 291.9 g are dissolved in 6860 g of absolute ethanol, and stearic acid is added. With the coating solution in which 136.8 g of magnesium (Mallinklot) was dispersed, 554.4 g of the above granules were coated and dried to obtain intermediate layer coated granules.
- magnesium Mallinklot
- hydroxypropylmethylcellulose phthalate (trade name: HP-55S, Shin-Etsu Chemical Co., Ltd.) and 45.3 g of diacetylino monoglyceride (trade name: Mybasset, Taest International Co., Ltd.) in 11045 g of 80% ethanol aqueous solution Dissolve and further disperse talc (trade name: talc, Matsumura Sangyo Co., Ltd.) 42.3 g, titanium oxide (trade name: Titanium (IV) Oxide, MERCK) 24. 3 g, and then add the above intermediate layer.
- the coated granules were coated to 1031.7 g and dried to obtain enteric granules.
- enteric granules 1603.8.8g into light anhydrous carboxylic acid (trade name: Japanese Pharmacopoeia AEROS IL-200, Nippon Aerosil Co., Ltd.) 15. Og and talc (trade name: Hyfiller # 17, Matsumura Sangyo ( 15. Add Og, mix using container mixer (trade name: 2Z5L container mixer, Toyo Packing Co., Ltd.), and force compound A to lmg per capsule. Filled the psel.
- Granules were produced in the same manner as in Formulation Example 1 according to the following formulation, and filled into capsules so that the total amount of Compound A was 10 mg per capsule.
- Non-barrel 108 (trade name, Freund industry)
- the sodium salt crystals (A, B, C and D crystals) obtained in Examples 2X, 4X, IX and 5X and the sodium salt amorphous form obtained in Example 9X, 3Y Tables 3 to 8 show chemical shifts of main peaks in the 13 C solid state NMR spectrum of the free amorphous material obtained in 1. In the table, the numerical range in Katsuko indicates that the peak is broad within this chemical shift range.
- the infrared absorption spectra of the crystals (ABC and D-type crystals of sodium salt) and amorphous materials obtained in each example are in accordance with the ATR method of the infrared spectrum measurement method described in the general test method of the Japanese Pharmacopoeia. Therefore, it was obtained by measurement under the following conditions.
- FTZIR 620 manufactured by JASCO Corporation
- Measurement method ATR method Measuring range: 4000cm ⁇ 650cm
- the infrared absorption spectrum (ATR method) of the sodium salt type A crystal obtained in Example 2X is shown in Fig. 12; the infrared absorption spectrum of the sodium salt type B crystal obtained in Example 4X (AT R method) ) In Fig. 13; Infrared absorption spectrum (ATR method) of the sodium salt C-type crystal obtained in Example IX in Fig. 14; Infrared of the D-type sodium salt crystal obtained in Example 5X Fig. 15 shows the absorption spectrum (ATR method); Fig. 16 shows the infrared absorption spectrum (ATR method) of the amorphous sodium salt obtained in Example 9X; Fig. 15 shows the free form obtained in Example 3Y.
- the infrared absorption spectrum (ATR method) of the amorphous material is shown in FIG.
- the crystals obtained in Examples 2X, 4X, IX and 5X (A, B, C and D crystals of the sodium salt) and the amorphous form of the sodium salt obtained in Example 9X and 3Y Tables 9 to 12 show the wavenumbers (cm- 1 ) of the main absorption peaks in the infrared absorption spectrum (ATR method) of the free amorphous material obtained in ( 1 ).
- the powder X-ray diffraction measurement of the crystals obtained in each Example was performed under the following measurement conditions in accordance with the powder X-ray diffraction measurement method described in the general test method of the Japanese Pharmacopoeia.
- Powder X-ray diffractometer RAD—1R (manufactured by Rigaku Corporation) (Example 1Z: Potassium salt) DISCOVER D8 with GADDS (Example 4Z (Zinc salt), 5Z (Calcium salt)) (Operation method)
- Example 1Z potassium salt
- Example 4Z zinc salt
- Example 5Z calcium salt
- Example 6X G salt of sodium salt
- Example 2Z Magnesium salt
- the powder X-ray diffraction pattern of the sodium salt A-type crystal obtained in Example 2X is shown in FIG. 18; the powder X-ray diffraction pattern of the sodium salt B-type crystal obtained in Example 4X is shown in FIG.
- the powder X-ray diffraction pattern of the sodium salt C-type crystal obtained in Example IX is shown in FIG. 20; the powder X-ray diffraction pattern of the sodium salt D-type crystal obtained in Example 5X is shown in FIG. 21;
- Example The powder X-ray diffraction pattern of the sodium salt E-type crystal obtained in 8X is shown in FIG. 22; the powder X-ray diffraction pattern of the sodium salt F-type crystal obtained in Example 10 X is shown in FIG. 23; Fig.
- FIG. 24 shows the powder X-ray diffraction pattern of the sodium salt G-type crystal obtained in Fig. 24;
- Fig. 25 shows the powder X-ray diffraction pattern of the sodium salt H-type crystal obtained in Example 7X;
- Fig. 26 shows the powder X-ray diffraction pattern of the amorphous sodium salt obtained.
- Fig. 27 shows the powder X-ray diffraction pattern of the amorphous sodium salt obtained in Example 9X;
- Fig. 28 shows the powder X-ray diffraction pattern of the free A-type crystal obtained;
- Fig. 29 shows the powder X-ray diffraction pattern of the free B-type crystal obtained in Example 2Y; obtained in Example 3Y.
- FIG. 30 shows the powder X-ray diffraction pattern of the free amorphous material.
- the magnesium salt crystals obtained in Example 2Z The powder X-ray diffraction pattern is shown in Fig. 31; the powder X-ray diffraction pattern of the potassium salt crystal obtained in Example 1Z is shown in Fig. 32; the powder X-ray diffraction of the lithium salt crystal obtained in Example 3Z.
- Figure 33 shows the powder X-ray diffraction pattern of the zinc salt crystal obtained in Example 4Z.
- Figure 34 shows the powder X-ray diffraction pattern of the calcium salt crystal obtained in Example 5Z. Respectively.
- the salt, crystal or amorphous form of the compound (1) of the present invention has an excellent gastric acid secretion inhibitory action, and also has excellent physical properties as a medical drug, and reflux esophagitis. It can be a useful drug for the treatment or prevention of symptomatic reflux esophagitis, gastric ulcer or duodenal ulcer. That is, according to the present invention, there are provided various salts, crystals, and amorphous bodies of the compound (1) that can be used as a manufacturing intermediate for a drug substance or a drug substance. be able to.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06821867A EP2077265A4 (en) | 2006-04-14 | 2006-10-13 | SALT OF SULFINYLBENZIMIDAZOLE DERIVATIVE, AND CRYSTAL AND AMORPHOUS FORM OF SAID SALT |
US12/296,902 US20090182149A1 (en) | 2006-04-14 | 2006-10-13 | Salt of sulfinylbenzimidazole compound, and crystal and amorphous form thereof |
CA2642835A CA2642835C (en) | 2006-04-14 | 2006-10-13 | Salt of sulfinylbenzimidazole compound, and crystal and amorphous form thereof |
CN2006800521799A CN101336240B (zh) | 2006-04-14 | 2006-10-13 | 亚磺酰基苯并咪唑化合物的盐、其结晶及无定形物 |
AU2006342614A AU2006342614A1 (en) | 2006-04-14 | 2006-10-13 | Salt of sulfinylbenzimidazole compound, and crystal and amorphous form thereof |
IL194478A IL194478A0 (en) | 2006-04-14 | 2008-10-02 | Salt of sulfinylbenzimidazole compound, and crystal and amorphous form thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPPCT/JP2006/307934 | 2006-04-14 | ||
PCT/JP2006/307934 WO2007122686A1 (ja) | 2006-04-14 | 2006-04-14 | ベンズイミダゾール化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007122755A1 true WO2007122755A1 (ja) | 2007-11-01 |
Family
ID=38624617
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/307934 WO2007122686A1 (ja) | 2006-04-14 | 2006-04-14 | ベンズイミダゾール化合物 |
PCT/JP2006/320496 WO2007122755A1 (ja) | 2006-04-14 | 2006-10-13 | スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/307934 WO2007122686A1 (ja) | 2006-04-14 | 2006-04-14 | ベンズイミダゾール化合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090182149A1 (ja) |
EP (1) | EP2077265A4 (ja) |
KR (1) | KR20080108406A (ja) |
CN (1) | CN101336240B (ja) |
AU (1) | AU2006342614A1 (ja) |
CA (1) | CA2642835C (ja) |
IL (1) | IL194478A0 (ja) |
WO (2) | WO2007122686A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017061559A (ja) * | 2009-01-30 | 2017-03-30 | ノバルティス アーゲー | 結晶質n−{(1s)−2−アミノ−1−[(3−フルオロフェニル)メチル]エチル}−5−クロロ−4−(4−クロロ−1−メチル−1h−ピラゾール−5−イル)−2−チオフェンカルボキサミド塩酸塩 |
US10449226B2 (en) | 2011-01-11 | 2019-10-22 | Novartis Ag | Combination |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7687456B2 (en) | 2005-11-09 | 2010-03-30 | Proteolix, Inc. | Compounds for enzyme inhibition |
NZ597545A (en) | 2006-06-19 | 2013-07-26 | Proteolix Inc | Peptide epoxyketones for proteasome inhibition |
JP5492417B2 (ja) * | 2006-10-13 | 2014-05-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 胃酸分泌抑制作用を有するベンズイミダゾール化合物 |
EP2207791B2 (en) | 2007-10-04 | 2019-08-07 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
MX368109B (es) | 2008-10-21 | 2019-09-18 | Onyx Therapeutics Inc | Terapia de combinacion con epoxicetonas peptidicas. |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
EP2542238B1 (en) | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
US8697646B2 (en) * | 2010-04-07 | 2014-04-15 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
WO2012095859A1 (en) * | 2011-01-12 | 2012-07-19 | Hetero Research Foundation | Polymorphs of dexlansoprazole salts |
US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59181277A (ja) * | 1983-02-11 | 1984-10-15 | アクチエボラゲツト・ヘツスレ | 新規な薬理学的に活性な化合物 |
JPH0222273A (ja) * | 1987-07-21 | 1990-01-25 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物およびその医薬用途 |
JPH05117268A (ja) * | 1991-10-22 | 1993-05-14 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物 |
JPH05507713A (ja) * | 1990-06-20 | 1993-11-04 | アクチエボラゲツト・アストラ | 置換ベンズイミダゾール、その製造方法およびその薬学的使用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69131627T2 (de) * | 1990-06-20 | 2000-04-27 | Astra Ab Soedertaelje | Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung |
SE521100C2 (sv) * | 1995-12-15 | 2003-09-30 | Astra Ab | Förfarande för framställning av en bensimidazolförening |
US20070015782A1 (en) * | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
EP1875911A4 (en) * | 2005-04-28 | 2010-03-03 | Eisai R&D Man Co Ltd | STABILIZED COMPOSITION |
KR20070112943A (ko) * | 2006-05-24 | 2007-11-28 | 엘지.필립스 엘시디 주식회사 | 전자잉크 패널과 이를 구비한 전자잉크 표시장치 및 그의구동방법 |
-
2006
- 2006-04-14 WO PCT/JP2006/307934 patent/WO2007122686A1/ja active Application Filing
- 2006-10-13 CA CA2642835A patent/CA2642835C/en not_active Expired - Fee Related
- 2006-10-13 US US12/296,902 patent/US20090182149A1/en not_active Abandoned
- 2006-10-13 WO PCT/JP2006/320496 patent/WO2007122755A1/ja active Application Filing
- 2006-10-13 AU AU2006342614A patent/AU2006342614A1/en not_active Abandoned
- 2006-10-13 CN CN2006800521799A patent/CN101336240B/zh not_active Expired - Fee Related
- 2006-10-13 KR KR1020087018378A patent/KR20080108406A/ko not_active Application Discontinuation
- 2006-10-13 EP EP06821867A patent/EP2077265A4/en not_active Withdrawn
-
2008
- 2008-10-02 IL IL194478A patent/IL194478A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59181277A (ja) * | 1983-02-11 | 1984-10-15 | アクチエボラゲツト・ヘツスレ | 新規な薬理学的に活性な化合物 |
JPH0222273A (ja) * | 1987-07-21 | 1990-01-25 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物およびその医薬用途 |
JPH05507713A (ja) * | 1990-06-20 | 1993-11-04 | アクチエボラゲツト・アストラ | 置換ベンズイミダゾール、その製造方法およびその薬学的使用 |
JPH05117268A (ja) * | 1991-10-22 | 1993-05-14 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2077265A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017061559A (ja) * | 2009-01-30 | 2017-03-30 | ノバルティス アーゲー | 結晶質n−{(1s)−2−アミノ−1−[(3−フルオロフェニル)メチル]エチル}−5−クロロ−4−(4−クロロ−1−メチル−1h−ピラゾール−5−イル)−2−チオフェンカルボキサミド塩酸塩 |
JP2019135237A (ja) * | 2009-01-30 | 2019-08-15 | ノバルティス アーゲー | 結晶質n−{(1s)−2−アミノ−1−[(3−フルオロフェニル)メチル]エチル}−5−クロロ−4−(4−クロロ−1−メチル−1h−ピラゾール−5−イル)−2−チオフェンカルボキサミド塩酸塩 |
US10449226B2 (en) | 2011-01-11 | 2019-10-22 | Novartis Ag | Combination |
Also Published As
Publication number | Publication date |
---|---|
EP2077265A4 (en) | 2010-09-08 |
EP2077265A1 (en) | 2009-07-08 |
CA2642835C (en) | 2014-12-02 |
US20090182149A1 (en) | 2009-07-16 |
IL194478A0 (en) | 2009-08-03 |
CN101336240B (zh) | 2011-06-29 |
KR20080108406A (ko) | 2008-12-15 |
CN101336240A (zh) | 2008-12-31 |
CA2642835A1 (en) | 2007-11-01 |
AU2006342614A1 (en) | 2007-11-01 |
WO2007122686A1 (ja) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007122755A1 (ja) | スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体 | |
JP6938561B2 (ja) | 重水素化2,4−チアゾリジンジオン及び治療方法 | |
JP5638515B2 (ja) | ピロール化合物 | |
RU2237666C2 (ru) | Калиевая соль (s)-омепразола, способ ее получения и фармацевтический препарат на ее основе | |
JP2011507977A (ja) | (r)−2−[[[3−メチル−4−(2,2,2−トリフルオロエトキシ)−2−ピリジニル]メチル]スルフィニル]−1h−ベンズイミダゾールの溶媒和物結晶形 | |
JP2001508805A (ja) | オメプラゾールナトリウム塩 | |
KR20040093187A (ko) | 란소프라졸 다형 및 그것의 제조 방법 | |
US9359328B2 (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof | |
JP5948252B2 (ja) | ベンズイミダゾール誘導体、並びにその医薬組成物及び使用 | |
JP2006501313A (ja) | (s)−パントプラゾールの塩及びその水和物 | |
WO2006001755A1 (en) | A new esomeprazole sodium salt crystal modification | |
RU2376304C2 (ru) | Моногидрат натриевой соли s-тенатопразола и его применение в качестве ингибитора протонного насоса | |
JP2002510293A (ja) | 抗潰瘍剤として新規なベンゾイミダゾール誘導体、それらの製造方法、及びそれらを含有する薬学的組成物 | |
EP1801110A1 (en) | Esomeprazole arginine salt | |
JP2007504223A (ja) | オメプラゾール及びエソメプラゾールiiの新規な塩 | |
CN105658645A (zh) | 作为mpge-1抑制剂的哌啶基苯并咪唑衍生物 | |
JP2008115173A (ja) | スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体 | |
JP2007504222A (ja) | オメプラゾール及びエソメプラゾールiの新規な塩 | |
JPWO2006132217A1 (ja) | ベンズイミダゾール化合物の塩の結晶 | |
RO122491B1 (ro) | Derivaţi de benzimidazol, alcoxi substituiţi, compoziţii farmaceutice care îi conţin şi utilizarea acestora | |
MXPA01007516A (en) | Potassium salt of (s |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06821867 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087018378 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052179.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2642835 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006342614 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006821867 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006342614 Country of ref document: AU Date of ref document: 20061013 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 194478 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12296902 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6088/CHENP/2008 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: JP |